Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and PK of Deucravacitinib Minitablets vs Tablets
NCT06851871Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Jan 2025; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06851871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851871.